

Jure Murgic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1510179/publications.pdf>

Version: 2024-02-01

64
papers

727
citations

687363

13
h-index

580821

25
g-index

64
all docs

64
docs citations

64
times ranked

1437
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
2	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
3	Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 561-567.	0.8	54
4	Tumor-Absorbed Dose Predicts Progression-Free Survival Following ¹³¹ I-Tositumomab Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1047-1053.	5.0	51
5	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
6	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	1.9	37
7	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.8	36
8	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
9	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 147-155.	0.5	28
10	Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. <i>Anticancer Research</i> , 2014, 34, 3177-84.	1.1	27
11	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.6	18
12	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
13	Time to Nadir PSA. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 465-471.	1.3	13
14	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020, , .	5.4	13
15	Oncologist Burnout Syndrome in Eastern Europe: Results of the Multinational Survey. <i>JCO Oncology Practice</i> , 2020, 16, e366-e376.	2.9	10
16	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
17	Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Genes</i> , 2022, 13, 383.	2.4	9
18	The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. <i>Radiation Oncology</i> , 2012, 7, 127.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Anatomic Variability of the Neurovascular Elements Defined by MRI. <i>Brachytherapy</i> , 2014, 13, S42-S43.	0.5	8
20	Quality of life of Croatian breast cancer patients receiving adjuvant treatment--comparison to long-term breast cancer survivors. <i>Collegium Antropologicum</i> , 2012, 36, 1335-41.	0.2	8
21	Sunitinib-induced thyrotoxicosis - a not so rare entity. <i>Anticancer Research</i> , 2015, 35, 481-5.	1.1	8
22	Breast and gynecological cancers in Croatia, 1988-2008. <i>Croatian Medical Journal</i> , 2012, 53, 100-108.	0.7	7
23	Radiation therapy in treatment of fibrodysplasia ossificans progressiva: a case report and review of the literature. <i>Collegium Antropologicum</i> , 2011, 35, 611-4.	0.2	7
24	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123.	4.5	5
25	Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy. <i>Brachytherapy</i> , 2019, 18, 567-573.	0.5	5
26	New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer. <i>Acta Medica Academica</i> , 2021, 50, 143.	0.8	5
27	Radiation Therapy for Cure or Palliation: Case of the Immunosuppressed Patient With Multiple Primary Cancers and Liver Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 581-582.	0.8	5
28	Splenic irradiation in hematologic malignancies and other hematologic disorders--single institution experience. <i>Acta Clinica Croatica</i> , 2011, 50, 29-35.	0.2	5
29	Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer. <i>Collegium Antropologicum</i> , 2012, 36, 325-9.	0.2	5
30	High-dose-rate brachytherapy and concurrent chemoradiotherapy followed by surgery for stage Ib-IIb cervical cancer: single institution experience. <i>Anticancer Research</i> , 2014, 34, 3861-6.	1.1	5
31	Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage. <i>Anticancer Research</i> , 2020, 40, 2323-2329.	1.1	4
32	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
33	Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 306-312.	0.5	3
34	Genetics of Prostate Carcinoma. <i>Acta Medica Academica</i> , 2021, 50, 71.	0.8	3
35	Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. <i>Radiation Oncology</i> , 2021, 16, 88.	2.7	3
36	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3

#	ARTICLE	IF	CITATIONS
37	The ageing of Croatian population. <i>Collegium Antropologicum</i> , 2009, 33, 701-5.	0.2	3
38	Postoperative use of radioiodine (131-I): review of recommendations and guidelines. <i>Collegium Antropologicum</i> , 2011, 35, 587-94.	0.2	3
39	Variation in External Sphincter Extension within and beyond the Prostate: Implications from MRI-Based Post Implant Segmental Dosimetry. <i>Brachytherapy</i> , 2013, 12, S33.	0.5	2
40	Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP). <i>ESMO Open</i> , 2016, 1, e000049.	4.5	2
41	Paget's disease in contralateral breast occurring 11 years after mastectomy for invasive ductal carcinoma. <i>Collegium Antropologicum</i> , 2009, 33, 327-9.	0.2	2
42	Familial Adenomatous Polyposis in Three Generations of a Single Family: A Case Study. <i>Case Reports in Oncology</i> , 2014, 7, 349-356.	0.7	1
43	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.8	1
44	In Regard to Lee et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1392-1394.	0.8	1
45	In Regard to van Son et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 617-618.	0.8	1
46	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 46-46.	1.6	1
47	Clinical recommendations for diagnosis, treatment and monitoring of patients with bladder cancer. <i>Lijecnički Vjesnik</i> , 2019, 141, .	0.0	1
48	Clinical guidelines development and usage: a critical insight and literature review: thyroid disease diagnostic algorithms. <i>Collegium Antropologicum</i> , 2008, 32, 1283-90.	0.2	1
49	An Analysis of Inter-Observer Variability in Catheter Reconstruction and Dosimetric Implications in Ultrasound-Based High-Dose-Rate Brachytherapy for Prostate Cancer. <i>Brachytherapy</i> , 2015, 14, S96.	0.5	0
50	MP14-04 OUTCOMES OF RADIATION FOLLOWING EXPECTANT MANAGEMENT FOR LOW RISK, LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
51	225: Assessment of Biochemical Outcome with Increasing Dose Escalation in Localized Prostate Cancer (PCA) With Precision Image-Guided Radiotherapy (IGRT). <i>Radiotherapy and Oncology</i> , 2016, 120, S82.	0.6	0
52	Assessment of Biochemical Outcomes with Increasing Dose Escalation in Localized Prostate Cancer (PCa) Treated with Precision Image Guided Radiation Therapy (IGRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E228-E229.	0.8	0
53	Radiotherapy in the Management of Prostate Cancer. <i>Medical Radiology</i> , 2017, , 87-112.	0.1	0
54	A Biopsy Based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S99.	0.8	0

#	ARTICLE	IF	CITATIONS
55	39 Determination of the Impact of Intratumoural Heterogeneity on Prognostic Biomarkers in Localized Prostate Cancer. Radiotherapy and Oncology, 2019, 139, S19-S20.	0.6	0
56	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2021, 39, 444-444.	1.6	0
57	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. Journal of Clinical Oncology, 2021, 39, e16526-e16526.	1.6	0
58	PP-0162 MR-assisted whole salvage HDR prostate brachytherapy with intra-prostatic boost: a prospective study. Radiotherapy and Oncology, 2021, 158, S124-S125.	0.6	0
59	Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.. Journal of Clinical Oncology, 2016, 34, 101-101.	1.6	0
60	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5051-5051.	1.6	0
61	Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , .		0
62	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. Journal of Clinical Oncology, 2017, 35, 42-42.	1.6	0
63	Comparison of conventionally fractionated and hypofractionated schedule for post-prostatectomy salvage radiotherapy: Early results from non-randomized observational study.. Journal of Clinical Oncology, 2017, 35, e551-e551.	1.6	0
64	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 68-68.	1.6	0